NZ604026A - Injectable flowable composition comprising buprenorphine - Google Patents

Injectable flowable composition comprising buprenorphine

Info

Publication number
NZ604026A
NZ604026A NZ604026A NZ60402611A NZ604026A NZ 604026 A NZ604026 A NZ 604026A NZ 604026 A NZ604026 A NZ 604026A NZ 60402611 A NZ60402611 A NZ 60402611A NZ 604026 A NZ604026 A NZ 604026A
Authority
NZ
New Zealand
Prior art keywords
buprenorphine
flowable composition
sustained release
delivery system
release delivery
Prior art date
Application number
NZ604026A
Other languages
English (en)
Inventor
Mingxing Zhou
Andrew Watkins
Richard L Norton
Original Assignee
Rb Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ604026(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rb Pharmaceuticals Ltd filed Critical Rb Pharmaceuticals Ltd
Publication of NZ604026A publication Critical patent/NZ604026A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ604026A 2010-06-08 2011-06-06 Injectable flowable composition comprising buprenorphine NZ604026A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1009549.5A GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine
PCT/GB2011/051057 WO2011154724A2 (en) 2010-06-08 2011-06-06 Compositions

Publications (1)

Publication Number Publication Date
NZ604026A true NZ604026A (en) 2015-01-30

Family

ID=42471306

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ604026A NZ604026A (en) 2010-06-08 2011-06-06 Injectable flowable composition comprising buprenorphine

Country Status (32)

Country Link
US (1) US8921387B2 (https=)
EP (3) EP3360538B1 (https=)
JP (2) JP5986072B2 (https=)
KR (1) KR101865689B1 (https=)
CN (1) CN103079544B (https=)
AU (1) AU2011263478B2 (https=)
BR (1) BR112012031290A2 (https=)
CA (1) CA2801676C (https=)
CL (1) CL2012003462A1 (https=)
CO (1) CO6670529A2 (https=)
CY (1) CY1120761T1 (https=)
DK (2) DK3360538T3 (https=)
ES (2) ES2939612T3 (https=)
FI (1) FI3360538T3 (https=)
GB (2) GB2513267B (https=)
HR (1) HRP20180118T1 (https=)
HU (1) HUE038275T2 (https=)
IL (2) IL223488A (https=)
LT (1) LT2579874T (https=)
MX (1) MX339209B (https=)
MY (1) MY171625A (https=)
NO (1) NO2579874T3 (https=)
NZ (1) NZ604026A (https=)
PL (1) PL2579874T3 (https=)
PT (1) PT2579874T (https=)
RS (1) RS56820B1 (https=)
RU (1) RU2607498C2 (https=)
SG (1) SG186200A1 (https=)
SI (1) SI2579874T1 (https=)
SM (1) SMT201800038T1 (https=)
WO (1) WO2011154724A2 (https=)
ZA (1) ZA201209233B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
WO2013126552A1 (en) 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
KR102082529B1 (ko) 2012-04-17 2020-02-27 퍼듀 퍼머 엘피 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
HRP20210068T1 (hr) * 2012-07-26 2021-03-05 Camurus Ab Opioidne formulacije
WO2014016428A1 (en) * 2012-07-26 2014-01-30 Camurus Ab Opioid formulations
WO2014093907A1 (en) * 2012-12-13 2014-06-19 A.P. Pharma, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9592227B2 (en) * 2013-03-15 2017-03-14 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
WO2018048460A1 (en) 2014-04-21 2018-03-15 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
DK3134070T3 (da) * 2014-04-21 2020-12-21 Heron Therapeutics Inc Sammensætninger af en polyorthoester og en organisk syre-excipiens
PT3134068T (pt) 2014-04-21 2021-10-18 Heron Therapeutics Inc Sistemas de libertação poliméricos de longa duração
PL3137081T3 (pl) 2014-04-28 2018-06-29 Orphomed, Inc. Dimer buprenorfiny i jego zastosowanie w leczeniu chorób układu pokarmowego
GB201419091D0 (en) * 2014-10-27 2014-12-10 Camurus Ab Formulations
CA3015557C (en) 2014-11-07 2019-07-16 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
JP6949820B2 (ja) * 2015-08-03 2021-10-13 トルマー インターナショナル リミテッド 薬物の持続投与のための液体ポリマー送達システム
US20200155449A1 (en) 2015-11-16 2020-05-21 Medincell Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
SG11201901294QA (en) 2016-09-13 2019-03-28 Alar Pharmaceuticals Inc Sustained-release buprenorphine formulations background of invention
AU2018283724B2 (en) 2017-06-16 2021-08-19 Indivior Uk Limited Methods to treat opioid use disorder
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
WO2019144079A1 (en) 2018-01-22 2019-07-25 Yuhua Li Pharmaceutical composition for sustained release delivery of buprenorphine
AR117426A1 (es) * 2018-05-11 2021-08-04 Alar Pharmaceuticals Inc Formulaciones inyectables de acción prolongada y formas cristalinas de derivados de buprenorfina
IL282120B2 (en) 2018-10-11 2025-08-01 Indivior Uk Ltd Buprenorphine to treat respiratory depression
US12403291B2 (en) 2019-08-30 2025-09-02 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform
CN118831057A (zh) * 2023-04-25 2024-10-25 深圳善康医药科技股份有限公司 丁丙诺啡植入剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
JP4259610B2 (ja) 1994-04-08 2009-04-30 キューエルティー・ユーエスエイ・インコーポレーテッド 液体デリバリー組成物
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
SI2561860T1 (en) * 2002-05-31 2018-05-31 Titan Pharmaceuticals, Inc. An implantable polymeric device for prolonged release of buprenorphine
RU2355385C2 (ru) * 2002-11-06 2009-05-20 Алза Корпорейшн Композиции пролонгированного действия с контролируемым высвобождением
JP2007525429A (ja) * 2003-03-11 2007-09-06 キューエルティー ユーエスエー，インコーポレイテッド． 細胞スケジュール依存性抗癌剤のための処方
MX2007003789A (es) * 2004-10-04 2007-07-20 Qlt Usa Inc Suministro ocular de formulaciones polimericas para suministro.
RS53890B1 (sr) * 2004-11-10 2015-08-31 Tolmar Therapeutics, Inc. Stabilizovan polimerni sistem za isporuku
DK3660073T3 (da) 2007-02-15 2023-09-18 Tolmar International Ltd Poly(lactid-co-glycolid) med lav sprængning
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
GB2481018A (en) 2011-12-14
SMT201800038T1 (it) 2018-03-08
KR101865689B1 (ko) 2018-06-08
SG186200A1 (en) 2013-01-30
HRP20180118T1 (hr) 2018-03-09
AU2011263478A1 (en) 2013-01-10
LT2579874T (lt) 2018-02-12
MY171625A (en) 2019-10-21
WO2011154724A3 (en) 2012-07-12
KR20130135026A (ko) 2013-12-10
GB201413064D0 (en) 2014-09-03
RS56820B1 (sr) 2018-04-30
PL2579874T3 (pl) 2018-05-30
CY1120761T1 (el) 2019-12-11
EP4218720A1 (en) 2023-08-02
CN103079544A (zh) 2013-05-01
GB2513267A (en) 2014-10-22
ZA201209233B (en) 2014-04-30
GB2513267B (en) 2015-03-18
EP2579874B1 (en) 2018-01-10
ES2939612T3 (es) 2023-04-25
GB201009549D0 (en) 2010-07-21
CO6670529A2 (es) 2013-05-15
DK2579874T3 (da) 2018-01-29
DK3360538T3 (da) 2023-03-06
US20130210853A1 (en) 2013-08-15
IL223488A (en) 2017-10-31
CN103079544B (zh) 2017-06-09
CA2801676C (en) 2018-08-07
EP3360538B1 (en) 2023-02-15
ES2656938T3 (es) 2018-03-01
WO2011154724A9 (en) 2012-08-16
JP6251774B2 (ja) 2017-12-20
HUE038275T2 (hu) 2018-10-29
JP2016155865A (ja) 2016-09-01
IL254417A0 (en) 2017-11-30
MX2012014335A (es) 2013-03-05
EP2579874A2 (en) 2013-04-17
JP5986072B2 (ja) 2016-09-06
CA2801676A1 (en) 2011-12-15
MX339209B (es) 2016-04-15
NO2579874T3 (https=) 2018-06-09
AU2011263478B2 (en) 2015-01-22
GB2481018B (en) 2015-03-18
RU2607498C2 (ru) 2017-01-10
CL2012003462A1 (es) 2013-04-01
US8921387B2 (en) 2014-12-30
JP2013533230A (ja) 2013-08-22
PT2579874T (pt) 2018-01-29
BR112012031290A2 (pt) 2016-11-01
FI3360538T3 (fi) 2023-03-22
SI2579874T1 (en) 2018-03-30
WO2011154724A2 (en) 2011-12-15
EP3360538A1 (en) 2018-08-15
RU2012157244A (ru) 2014-07-20

Similar Documents

Publication Publication Date Title
NZ604026A (en) Injectable flowable composition comprising buprenorphine
NZ604342A (en) Antipsychotic injectable depot composition
WO2007038246A3 (en) Solid polymer delivery compositions and methods for use thereof
WO2007084460A3 (en) Pharmaceutical compositions with enhanced stability
WO2008054772A3 (en) Implantable elastomeric caprolactone depot compositions and uses thereof
MY140155A (en) Controlled release depot formulations
NZ597621A (en) Sustained delivery formulations of risperidone compounds
BRPI0514297A (pt) composições farmacêuticas para liberação controlada de compostos biologicamente ativos
WO2008041246A3 (en) Injectable depot composition and its' process of preparation
JP2014240439A5 (https=)
CA2468703A1 (en) Controlled release polymeric compositions of bone growth promoting compounds
MXPA05013003A (es) Composiciones de deposito elastomerico implantables, usos de las mismas y metodo para elaboracion.
AR065039A1 (es) Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso
WO2011109732A3 (en) Reverse thermal gels and uses therefor
MX374955B (es) Formulación de implantes de risperidona o paliperidona.
WO2011126839A3 (en) Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
RU2011136636A (ru) Фармацевтическая композиция для орального введения
SA520412229B1 (ar) تركيبات صيدلية لها فترة إطلاق مُختارة
NZ606723A (en) Glatiramer acetate molecular weight markers
WO2011060195A3 (en) Topical etoricoxib formulation comprising an eutectic mixture of permeation enhancers
WO2012147101A3 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
WO2010132730A3 (en) Hyaluronic acid (ha) injection vehicle
RU2014153760A (ru) Водные гелеобразующие композиции растворимых активных фармацевтических пептидов, обеспечивающие модифицированное высвобождение
IN2014MN02651A (https=)
ZA200805598B (en) Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2016 BY COMPUTER PACKAGES INC

Effective date: 20150731

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2017 BY COMPUTER PACKAGES INC

Effective date: 20160518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2018 BY COMPUTER PACKAGES INC

Effective date: 20170518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2019 BY CPA GLOBAL

Effective date: 20180510

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2020 BY CPA GLOBAL

Effective date: 20190425

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2021 BY CPA GLOBAL

Effective date: 20200424

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2022 BY COMPUTER PACKAGES INC

Effective date: 20210517

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2023 BY COMPUTER PACKAGES INC

Effective date: 20220519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2024 BY COMPUTER PACKAGES INC

Effective date: 20230518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2025 BY COMPUTER PACKAGES INC

Effective date: 20240517

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2026 BY COMPUTER PACKAGES INC

Effective date: 20250517